Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia-Reference-Cited by-同舟云学术

Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia

Published:2017-01-17 Issue:13 Volume:23 Page:3385-3395
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Han Lina,Jorgensen Jeffrey L.,Brooks Chris,Shi Ce,Zhang Qi,Nogueras González Graciela M.,Cavazos Antonio,Pan Rongqing,Mu Hong,Wang Sa A.,Zhou Jin,AI-Atrash Gheath,Ciurea Stefan O.,Rettig Mike,DiPersio John F.,Cortes Jorge,Huang Xuelin,Kantarjian Hagop M.,Andreeff Michael,Ravandi Farhad,Konopleva Marina

Funder

NIH/NCI

National Natural Science Foundation of China

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting CD25+ lymphoma cells with the antibody–drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agents;British Journal of Haematology;2024-07-30

2. EP300-ZNF384 transactivates IL3RA to promote the progression of B-cell acute lymphoblastic leukemia;Cell Communication and Signaling;2024-04-02

3. Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study;The Lancet Oncology;2024-03

4. Plasmacytoid dendritic cell expansion in myeloid neoplasms: A novel distinct subset of myeloid neoplasm?;Critical Reviews in Oncology/Hematology;2023-12

5. Blastic Plasmacytoid Dendritic Cell Neoplasm;Advances in Molecular Pathology;2023-11